Universität zu Köln

Broeckelmann, Paul J., McMullen, Suzanne, Ben Wilson, J., Mueller, Kerstin, Goring, Sarah, Stamatoullas, Aspasia, Zagadailov, Erin, Gautam, Ashish, Huebner, Dirk, Dalal, Mehul and Illidge, Tim (2019). Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br. J. Haematol., 184 (2). S. 202 - 215. HOBOKEN: WILEY. ISSN 1365-2141

Full text not available from this repository.

Abstract

First-line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP(escalated) (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography-driven strategies and ABVD or BEACOPP variants incorporating the antibody-drug conjugate brentuximab vedotin (BV) or anti-PD1 antibodies are under investigation in advanced-stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPP(escalated) and BV-AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross-sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression-free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5-year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians' recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians' treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED McMullen, Suzanne UNSPECIFIED UNSPECIFIED UNSPECIFIED Ben Wilson, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Goring, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Stamatoullas, Aspasia UNSPECIFIED UNSPECIFIED UNSPECIFIED Zagadailov, Erin UNSPECIFIED UNSPECIFIED UNSPECIFIED Gautam, Ashish UNSPECIFIED UNSPECIFIED UNSPECIFIED Huebner, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Dalal, Mehul UNSPECIFIED UNSPECIFIED UNSPECIFIED Illidge, Tim UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-140307
DOI:	10.1111/bjh.15566
Journal or Publication Title:	Br. J. Haematol.
Volume:	184
Number:	2
Page Range:	S. 202 - 215
Date:	2019
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1365-2141
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language BRENTUXIMAB VEDOTIN; OPEN-LABEL; STAGE-III; 8 CYCLES; SURVIVORS; RISK; ABVD; TRIAL; IV Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14030